s丧失后的生活：乙型肝炎的抗原丧失对未来患者结果的影响

StephenW

Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes
Daniel Q Huang  1   2 , Seng Gee Lim  1   2
Affiliations
Affiliations

    1
    Division of Gastroenterology and Hepatology Department of Medicine National University Hospital Singapore.
    2
    Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore.

    PMID: 33489099 PMCID: PMC7805298 DOI: 10.1002/cld.983
Chronic hepatitis B (CHB) affects an estimated 257 mil-lion people worldwide and contributed to 887,000 deaths in  2015  alone.1  Hepatitis  B  s  antigen  (HBsAg)  is  present  in 3.6% of the world’s population,2 and 12% to 20% of patients  with  CHB  go  on  to  experience  development  of  liver  cirrhosis.  Among  the  individuals  with  cirrhosis,  20%  to 23% experience development of liver decompensation, and 6% to 15% experience development of hepatocellu-lar carcinoma (HCC).3The presence of covalently closed circular DNA and hepatitis B virus (HBV) integration into DNA makes complete removal  of  HBV  unlikely  with  current  antiviral  strategies.  An international workshop involving European Association for the Study of the Liver and American Association for the Study of Liver Diseases concluded that functional cure, or HBsAg loss 6 months after stopping therapy, is an accept-able goal of therapy.

StephenW

s丧失后的生活：乙型肝炎的抗原丧失对未来患者结果的影响
Daniel Q Huang 1 2，Seng Gee Lim 1 2
隶属关系
隶属关系

    1个
    新加坡国立大学医院消化内科和肝病科。
    2
    新加坡国立大学医学院林永林医学院。

    PMID：33489099 PMCID：PMC7805298 DOI：10.1002 / cld.983
慢性乙型肝炎（CHB）估计影响全球2.57亿人口，仅在2015年就造成887,000例死亡。1乙型肝炎s抗原（HBsAg）占世界人口的3.6％，2和12％至20％ CHB患者继续经历肝硬化的发展。在肝硬化患者中，肝失代偿的发生率为20％至23％，肝细胞癌（HCC）的发生为6％至15％。3存在共价闭合的环状DNA和乙型肝炎病毒（HBV）整合到DNA中使得目前的抗病毒策略不可能完全清除HBV。由欧洲肝病研究协会和美国肝病研究协会组成的国际研讨会得出结论，功能治疗或停止治疗后6个月HBsAg丢失是可接受的治疗目标。

StephenW

https://aasldpubs.onlinelibrary. ... ect/10.1002/cld.983